摘要
背景与目的:骨肉瘤是一种具有高度侵袭性的恶性肿瘤,目前应用化疗联合手术的治疗策略5年生存率仅为40%~60%,近期多项研究认为骨肉瘤细胞株中可能存在肿瘤干细胞。本研究旨在分离和鉴定骨肉瘤细胞株MG-63中的骨肉瘤干细胞样细胞。方法:用免疫磁珠分选法分离人骨肉瘤细胞株MG-63中的CD133+细胞,应用流式细胞学分析、蛋白质印迹法(Western blot)检测和免疫荧光染色测定CD133+细胞的纯度,应用CCK-8法、平板集落形成试验、划痕试验及Transwell侵袭小室试验,研究CD133+细胞的生物学特性。结果:本研究成功地从MG-63中获得CD133+细胞。流式细胞学分析、免疫荧光染色和Western blot分析显示该细胞群中高表达CD133(纯度约90%～95%);CD133+细胞的增殖、平板集落形成能力、迁移能力及侵袭能力均强于CD133-细胞(P<0.05)。结论:人骨肉瘤MG-63细胞株中存在肿瘤干细胞样细胞,CD133可能是骨肉瘤的干细胞标志物之一。
Background and purpose： Osteosarcoma is a highly aggressive malignancy with a 5-year survival rate about 40%-60% after the treatment strategies of surgery combined with chemotherapy. Recent studies indicated that cancer stem cells may exist in osteosarcoma cells. Our study was aimed to isolate and identify cancer stem-like cells from the osteosarcoma cell line MG-63. Methods： By using magnetic activated cell sorting, we separated CD133＋ and CD133 cells in MG-63 cell line. Biological characteristics of osteosarcoma stem cells were studied using CCK-8 method, plat colony formation test, scratch wound-healing assay and transwell invasion assay. Results： We separated CD133＂ and CD133- cells in MG-63 cell line, CD133＋ cells showed stronger ability of proliferation, colony formation, migration and invasion than the CD133- cells. Conclusion： There were cancer stem- like cells in osteosarcoma cell line MG-63, CD133 could be one of the osteosarcoma stem cell markers.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2012年第10期729-734,共6页
China Oncology
基金
国家自然科学基金(No:81001191)
上海市科委基金资助项目(No:10PJ1408300)
